The market may have been dragged lower by the resources sector today, but that hasn't stopped some shares from pushing notably higher.
Three at the small end of the market climbing higher today are listed below:
The Acrux Limited (ASX: ACR) share price has jumped 13% to 17.5 cents after the drug delivery company advised that it has submitted its first-to-file application for a generic version of the Jublia product, making it eligible for 180 days of generic exclusivity. Jublia is an FDA approved topical treatment of onychomycosis, also known as tinea unguium. Onychomycosis is a fungal infection of the nail that can result in thickening and yellowing of the nail and ultimately the separation from the nail bed. Annual sales of Jublia exceeded US$280 million for the 12 months ended March 2018.
The Money3 Corporation Limited (ASX: MNY) share price has climbed 3% to $2.08 after the financial services company upgraded its earnings guidance and dividend outlook. Management expects to report a full-year net profit after tax of approximately $32 million in FY 2018. As a result, it intends to raise its final dividend to 4.5 cents per share, bringing its full-year dividend to 9 cents per share. This means its shares provide a fully franked 4.3% yield, which I think makes it a great option for income investors.
The Resapp Health Ltd (ASX: RAP) share price has pushed higher for a second day in a row and is up a further 3% to 17 cents. Yesterday the healthcare technology company advised that its Smartcough-C-2 study enrolment was complete in the United States, whereas today its Breathe Easy study in Australia has completed its enrolment. Both sets of results are expected within the next couple of months. It certainly will be an exciting time for shareholders if the results of these studies come back favourably. Though, it is worth remembering that when its previous study failed the share price plunged significantly.
